Delivery Order SPE2DB20D2014-SPE2DB25FC73J
- Not listed
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. This is a firm fixed-price delivery order with a ceiling value of $3,763.02 and an ultimate completion date of July 28, 2025. The contract was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,477.61 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by August 26, 2025. The product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) with a ceiling value of $2,868.78. This is a firm fixed price delivery order with an ultimate completion date of August 25, 2025, and represents a non-competitive, non-set-aside award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $1,357.46 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in a 150 mL quantity. The contract is structured as a firm fixed price delivery order with a completion date of September 9, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This is a non-set-aside award, indicating the contract was competitively procured through open competition. This...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $2,915.25. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The contract is scheduled for completion by June 3, 2025, with performance taking place at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $1,375.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 150 ml quantities. The contract, which is non-set-aside and competitively awarded, is scheduled for completion by June 3, 2025, with performance conducted at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $2,276.24 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) on September 15, 2025, with an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through...
- The Defense Logistics Agency awarded a delivery order valued at $1,577.04 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) on July 29, 2025, with completion scheduled for July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $4,515.00 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities. This is a firm fixed-price delivery order with a completion date of August 19, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC73JDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, valued at $4,567.35. This delivery order represents a firm fixed price, non-set-aside contract utilizing AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 14, 2025. This award is issued under AmerisourceBergen Drug Corp's DLA Troop Support Medical Indefinite Delivery Contract (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor specializing in federal medical procurement, AmerisourceBergen has consistently delivered brand-name and generic medications, vaccines, and medical supplies to support military healthcare systems and other federal agencies. Quillivant XR, a medication commonly used for attention deficit hyperactivity disorder treatment, is part of the company's comprehensive pharmaceutical product portfolio supplied through this global prime vendor contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.6k | 8/13/25 |